Codexis appoints Cynthia Collins to Board of Directors as Class II director

CODEXIS, INC.

Appointed effective March 28, 2025 as Class II director; term expires at 2027 annual meeting.
Board determined Collins is independent under Nasdaq rules; appointed to Compensation Committee.
Previously CEO of Editas Medicine (2019-2021); currently Executive Chair/Interim CEO of Nutcracker Therapeutics.
Receives $50k annual cash retainer plus $20k for committee; initial RSU grant of ~$200k vesting over 3 years.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Cynthia Collins

Member of the Board, Class II Director

CDXS · CODEXIS, INC.

Effective: 2025-03-28
Filed: March 31, 2025, 7:59 PM ET

On March 28, 2025, the Board of Directors (the “Board”) of Codexis, Inc. (the “Company”), upon the recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Cynthia Collins as a member of the Board as a Class II director, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Cynthia Collins was appointed as Member of the Board, Class II Director at CODEXIS, INC..

Action: appointed
Role: Member of the Board, Class II Director

Exact text from the filing

On March 28, 2025, the Board of Directors (the “Board”) of Codexis, Inc. (the “Company”), upon the recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Cynthia Collins as a member of the Board as a Class II director, effective immediately.

View on SEC.gov

CODEXIS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-25-067978

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.